Alnylam retains key elements in Kreutzer-Limmer I patent

By Elaine Rigoli

Tampa, Fla., June 22 - Alnylam Pharmaceuticals, Inc. said Thursday that the European Patent Office has upheld key features of the company's Kreutzer-Limmer I patent (EP 1144623) with claims covering small interfering RNAs (siRNAs), the molecules that mediate RNAi.

This patent was originally granted in Europe on Aug. 28, 2002 but was opposed by several parties.

The amended patent claims cover certain structural requirements for siRNAs that are important for therapeutic activity.

Alnylam is a biopharmaceutical company with headquarters in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.